# 🔻 Hypophosphatemia ## 🔬 Calcium-Phosphate Homeostasis Overview **Understanding the System:** Hypophosphatemia results from decreased intestinal absorption, increased renal losses (via PTH or FGF23), or intracellular shifts. The kidneys (red) reabsorb 85-90% of filtered phosphate. FGF23 disorders cause severe phosphate wasting and rickets/osteomalacia. ## 🚨 EMERGENCY PROTOCOL: Severe Hypophosphatemia (\<1.0 mg/dL) 1 **IV Phosphate:** 0.08-0.16 mmol/kg over 6 hours (max 0.24 mmol/kg) 2 **Monitor Closely:** Check PO₄, Ca, K, Mg q4-6h 3 **Watch for Complications:** Hypocalcemia, hyperkalemia, renal failure 4 **Correct Other Electrolytes:** K⁺, Mg²⁺ often low 5 **Respiratory Support:** Monitor for muscle weakness **⚠️ Critical Manifestations:** Respiratory failure, rhabdomyolysis, hemolytic anemia, cardiac dysfunction! ## 📊 Clinical Presentation by Severity ### Mild (2.0-2.5 mg/dL) - Usually asymptomatic - Mild fatigue - Bone pain (chronic) ### Moderate (1.0-2.0 mg/dL) - Weakness, myalgias - Impaired leukocyte function - Paresthesias - Confusion ### Severe (\<1.0 mg/dL) - Respiratory failure - Rhabdomyolysis - Hemolytic anemia - Seizures, coma - Heart failure ## 🔬 Clinical Manifestations #### 🫁 Respiratory - Diaphragm weakness - Respiratory failure - Difficulty weaning ventilator #### 💪 Muscular - Proximal myopathy - Rhabdomyolysis - Dysphagia #### 🩸 Hematologic - Hemolytic anemia - ↓2,3-DPG (↓O₂ delivery) - Impaired WBC function - Platelet dysfunction #### 🦴 Skeletal - Osteomalacia (adults) - Rickets (children) - Bone pain - Fractures #### 🧠 Neurologic - Confusion, irritability - Paresthesias - Seizures (rare) - Metabolic encephalopathy #### ❤️ Cardiac - Cardiomyopathy - Heart failure - Arrhythmias ## 🔍 Etiology and Pathophysiology ### 📉 Decreased Absorption - **Malnutrition/Alcoholism** (most common) - Malabsorption syndromes - Chronic diarrhea - Vitamin D deficiency - Phosphate binders (excessive) - Antacids (aluminum, magnesium) ### 🚰 Increased Renal Losses - **Primary hyperparathyroidism** - FGF23 disorders (XLH, TIO) - Fanconi syndrome - Post-kidney transplant - Volume expansion - Diuretics - Glucocorticoids ### ➡️ Intracellular Shifts - **Refeeding syndrome** - Insulin administration - Respiratory alkalosis - Hungry bone syndrome - Rapid cell proliferation - Treatment of DKA ### ⚠️ REFEEDING SYNDROME - High Risk Patients #### Risk Factors: - BMI \<16 kg/m² - Weight loss \>15% in 3-6 months - Little/no intake for \>10 days - Low baseline K⁺, PO₄, or Mg²⁺ - Chronic alcoholism - Anorexia nervosa #### Prevention Protocol: - Start feeding at 10-20 kcal/kg/day - Increase slowly over 4-7 days - Thiamine 200-300 mg daily BEFORE feeding - Monitor PO₄, K⁺, Mg²⁺ daily × 1 week - Supplement prophylactically ### 🧬 FGF23-Mediated Disorders #### X-Linked Hypophosphatemia (XLH) - PHEX gene mutation - ↑FGF23 → renal PO₄ wasting - Rickets, short stature, bone deformities - Dental abscesses - Treatment: Burosumab (anti-FGF23 antibody) #### Tumor-Induced Osteomalacia (TIO) - Mesenchymal tumors secrete FGF23 - Severe muscle weakness, bone pain - Often occult tumors (difficult to locate) - Treatment: Tumor resection if possible - Burosumab if unresectable **Common Features:** ↑FGF23, ↓1,25(OH)₂D (inappropriately low), renal phosphate wasting, normal PTH/calcium ## 🔬 Diagnostic Approach ### Step-by-Step Evaluation 1 **Confirm Hypophosphatemia:** PO₄ \<2.5 mg/dL (fasting preferred) 2 **Check Urine Phosphate:** - 24hr urine PO₄ \<100 mg = GI losses/shifts - 24hr urine PO₄ \>100 mg = renal losses - FePO₄ \>5% = inappropriate renal wasting 3 **If Renal Losses, Check:** - **PTH:** ↑ in hyperparathyroidism - **25-OH Vitamin D:** Screen for deficiency - **1,25(OH)₂ Vitamin D:** Inappropriately low in FGF23 disorders - **FGF23:** ↑ in XLH, TIO 4 **Additional Testing:** - Glucose, aminoaciduria (Fanconi syndrome) - Imaging for tumors if TIO suspected - Genetic testing for hereditary disorders ## 🧮 Phosphate Replacement Calculator Current Phosphate (mg/dL): 1.5 Patient Weight (kg): 70 **Estimated Deficit: 7.0 mmol**\ IV Dose: 0.10 mmol/kg = 7.0 mmol over 6 hours\ Oral: Neutra-Phos 2 packets TID × 2-3 days ## 💊 Treatment Strategies ### Acute Replacement [TABLE] ### Chronic Management by Etiology #### Nutritional Deficiency - **Diet:** High phosphate foods (dairy, meat, nuts, beans) - **Supplements:** 1-3 g daily in divided doses - **Vitamin D:** If deficient (enhances absorption) - **Address underlying:** Alcoholism, malabsorption #### Primary Hyperparathyroidism - **Definitive:** Parathyroidectomy - **Medical:** Phosphate supplements (limited efficacy) - **Monitor:** Can worsen hypercalcemia #### X-Linked Hypophosphatemia (XLH) ##### Traditional Therapy: - Phosphate 1-3 g/day in 4-5 doses - Calcitriol 0.5-1 mcg/day - Monitor for nephrocalcinosis - Suboptimal outcomes ##### Burosumab (Game Changer): - Anti-FGF23 monoclonal antibody - 0.4-2.0 mg/kg SC q2 weeks - Normalizes phosphate - Improves growth, rickets, pain - FDA approved for XLH and TIO #### Tumor-Induced Osteomalacia - **Localize tumor:** Octreotide scan, FDG-PET, MRI - **Surgical resection:** Curative if tumor found - **If unresectable:** Burosumab or phosphate + calcitriol - **Monitor:** FGF23 levels post-resection ## 🎯 Key Clinical Pearls - Symptoms appear at PO₄ \<2.0 mg/dL; severe at \<1.0 mg/dL - Respiratory muscle weakness → difficulty weaning from ventilator - Rhabdomyolysis risk highest when PO₄ \<1.0 mg/dL - Refeeding syndrome: Most common in malnourished patients - PREVENT! - Always give thiamine BEFORE feeding malnourished patients - Check urine phosphate to distinguish GI vs renal losses - FePO₄ \>5% = inappropriate renal wasting (should conserve if low) - Primary hyperparathyroidism: Most common cause of renal losses - FGF23 disorders: Low 1,25(OH)₂D despite hypophosphatemia (paradox!) - IV phosphate: Never exceed 0.24 mmol/kg - risk of acute hypocalcemia - Oral phosphate causes diarrhea - divide doses, take with meals - Alcoholics: Triple threat - poor intake, ↑renal losses, vitamin D deficiency - Post-parathyroidectomy: Hungry bone syndrome can cause severe hypophosphatemia - Burosumab revolutionized treatment of XLH - consider for refractory cases ## 📚 Special Populations ### Critical Care - Common in ICU (30-50%) - Ventilator weaning difficulty - Check before extubation - IV replacement if \<1.5 mg/dL - Monitor for refeeding syndrome ### Post-Transplant - Persistent hyperparathyroidism - FGF23 remains elevated - Usually resolves in months - Oral supplements usually sufficient ### Pediatric - Rickets presentation - Growth retardation - Consider genetic causes - XLH most common inherited form - Burosumab if XLH confirmed ## 🔄 Monitoring and Follow-up ### Replacement Monitoring **During IV Replacement:** PO₄, Ca, K, Mg q4-6h **Oral Replacement:** Daily × 3-5 days, then weekly **Chronic Therapy:** Monthly initially, then q3-6 months **XLH on Burosumab:** PO₄ monthly, adjust dose to maintain normal --- [Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/electrolytes/phosphorus/hypophosphatemia.html) · Markdown synchronized October 3, 2026.